Press releases
- Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for First Two Evolysse™ Dermal Filler Products
- Evolus Broadens International Presence with Launch of Nuceiva® (botulinum toxin type A) in Spain
- Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Evolus Announces Positive Data from Pivotal Trial for First Two Evolysse™ Dermal Filler Products at 2024 SCALE Meeting
- Evolus Celebrates Fifth Anniversary of Launching its Flagship Product Jeuveau® at the Women’s Wear Daily Beauty CEO Summit
- Evolus’ Sandra Beaver Named Orange County Business Journal’s Public Company CFO of the Year
- Evolus Reports First Quarter 2024 Results and Provides Business Update
- Evolus to Report First Quarter Financial Results on May 7, 2024
- Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for “Extra-Strength” 40U Formulation of Jeuveau®
More ▼
Key statistics
As of last trade, Evolus Inc (EVL:MUN) traded at 9.90, 51.15% above the 52 week low of 6.55 set on Jul 25, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 9.90 |
---|---|
High | 9.90 |
Low | 9.90 |
Bid | 9.70 |
Offer | 9.90 |
Previous close | 9.90 |
Average volume | 25.44 |
---|---|
Shares outstanding | 62.61m |
Free float | 48.93m |
P/E (TTM) | -- |
Market cap | 658.04m USD |
EPS (TTM) | -1.05 USD |
Data delayed at least 15 minutes, as of Jun 26 2024 07:03 BST.
More ▼